Tetrofosmin is a diphosphine complexed with technetium 99 used for imaging to determine myocardial ischemia, infarcted myocardium, and assessment of left ventricular function. Tetrofosmin was developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds.
- Mechanism
- Curator reviewed · 2 references
Tetrofosmin normal biodistribution makes it suitable to be used as a myocardial agent as it is uptaken by the myocardial tissue and it presents a very low redistribution after 3-4 hours of administration. After distribution, tetrofosmin is a lipophilic cationic agent which is passively diffused and accumulated in viable myocardial tissue.
- Primary indication
- Tetrofosmin is indicated to be used as a complex with technetium Tc-99m for scintigraphic imaging of the myocardium following separate administrations under exercise and/or resting conditions.Curator reviewed · 7 structured indications
- Formula / weight
- C18H40O4P2 · 382.462 g/mol (avg)
- First approval
- United States, 1996
- Code names
- P-53
Resolves to
QCWJONLQSHEGEJ-UHFFFAOYSA-NSMILESCCOCCP(CCOCC)CCP(CCOCC)CCOCCWhat you can answer from here — as of July 06, 2026
Which other approved drugs treat the same conditions as Tetrofosmin, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account